ASTRAZENECA PHARMACEUTICALS LP - NEW AWARD FOR ACALABRUTINIB TABLETS (100 MG) WITH ASTRAZENECA PHARMACEUTICALS, LP. PERIOD OF PERFORMANCE IS 06/24/2024 TO 06/23/2025 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR ACALABRUTINIB TABLETS (100 MG) WITH ASTRAZENECA PHARMACEUTICALS, LP. PERIOD OF PERFORMANCE IS 06/24/2024 TO 06/23/2025 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Jan 14, 2026, Department of Veterans Affairs to ASTRAZENECA PHARMACEUTICALS LP for new award for acalabrutinib tablets (100 mg) with astrazeneca pharmaceuticals, lp. period of performance is 06/24/2024 to 06/23/2025 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 3 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.